Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 2/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14538249 | 0.90 | PLA2G10 (0.61) | HDAC8HDAC6ACHEPLA2G10PLA2G2A | |
| SCHEMBL3735193 | 0.85 | HRH3 (0.58) | HDAC8HDAC6ACHEHRH3PLA2G10 | |
| SCHEMBL13679679 | 0.84 | HDAC8 (0.68) | HDAC8HDAC6ACHEHRH3BCHE | |
| SCHEMBL4289838 | 0.82 | HDAC8 (0.66) | HDAC8HDAC6ACHEHRH3BCHE | |
| SCHEMBL540981 | 0.82 | HRH3 (0.71) | HDAC8HDAC6ACHEHRH3HTT | |
| SCHEMBL4928369 | 0.81 | ACHE (0.49) | HDAC8HDAC6ACHEHRH3PLA2G10 | |
| SCHEMBL6582716 | 0.81 | HDAC6 (0.75) | HDAC8HDAC6ACHEHRH3HTT | |
| SCHEMBL12131039 | 0.81 | HDAC8 (0.60) | HDAC8HDAC6ACHEHRH3BCHE | |
| Hydrochloric Acid SCHEMBL6297059 | 0.81 | HDAC8 (0.64) | HDAC8HDAC6ACHEHRH3BCHE | |
| SCHEMBL5393101 | 0.81 | HDAC8 (0.64) | HDAC8HDAC6ACHEHRH3BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101151268-A | Hydrazinocarbonyl-thieno[2,3-c]pyrazoles, preparation method, compositions containing same and use | AVENTIS PHARMA SA (FR) | 2008-03-26 | — | — | CN | disclosed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| EP-1115707-A1 | BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | disclosed |
| EP-1077931-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca AB (SE) | 2001-02-28 | — | — | EP | disclosed |
| WO-2000018738-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | disclosed |
| US-6030984-A | 7-(4-PHENOXYPHENYL)-6-OXOQUINOLIZINES AND DERIVATIVES OF TRICYCLIC RING ANALOGUES, PARTICULARLY 7-OXOTHIENO-(2,3-A)QUINOLIZINE; INHIBITING BETA-AMYLOID PEPTIDE ACTIVITY | HOFFMANN-LA ROCHE INC. (US) | 2000-02-29 | — | — | US | disclosed |
| WO-1999059959-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 1999-11-25 | — | — | WO | disclosed |
| US-5869500-A | INHIBITING BETA-AMYLOID PEPTIDE ACTIVITY | HOFFMANN-LA ROCHE INC. (US) | 1999-02-09 | — | — | US | disclosed |
| WO-1998025930-A2 | USE OF BI- AND TRICYCLIC PYRIDONE DERIVATIVES AGAINST ALZHEIMER'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | OPRL1, OPRM1, SIGMAR1 | HDAC8 2249/4885HDAC6 475/4885ACHE 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.